Green Cross Cell Unveils Positive Progress In HCC Immunotherapy
This article was originally published in PharmAsia News
Executive Summary
During the latest meeting of the Asian Cellular Therapy Organization, South Korea's Green Cross Cell revealed Phase III results for its Immuncell-LC immunotherapy for early stage liver cancer, which the company said resulted in reduced recurrence cut mortality rates.